Insulet Aktie

Insulet EBITDA

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Insulet (PODD) pr. 13. aug. 2026 er 473,80 Mio. USD. I foregående år var EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) 308,90 Mio. USD — en ændring på 53,38 % (højere).

EBITDA

473,80 Mio.USD

YoY

53,38%

Senest opdateret:

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Insulet er 2026 473,80 Mio. USD. EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Insulet var 2025 308,90 Mio. USD. Det falder dermed med 53,38% højere sammenlignet med året før.
Access this data via the Eulerpool API

Insulet Aktieanalyse

Hvad laver Insulet? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Insulet aktie

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Insulet er 473,80 Mio. USD i 2026.

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Insulet ændrede sig fra 308,90 Mio. USD til 473,80 Mio. USD, hvilket repræsenterer en ændring på 53,38 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) Insulet siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA måler driftsresultatet før virkningen af finansieringsstruktur, skattesystem og ikke-kontante afskrivninger.

EBITDA = EBIT + Af- og nedskrivninger

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s USD er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s Insulet historisk.

Access this data via the Eulerpool API

Resultatopgørelse — Insulet

Alle nøgletal — Insulet